Company ProfilePremium

CTK Co., Ltd (formerly CTK Cosmetics Co., Ltd)

Company Profile Analysis

Ticker: 260930.KQ주식회사 씨티케이

ESOMAR 23 Corporate BadgeISO Certifications Badge
CTK Co., Ltd - Company showcase

Year Founded & Workforce

2001

129 Employees

CTK Co., Ltd logo

CTK Co., Ltd Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

CTK Co., Ltd Overview

CTK is a Seoul-based "factory-free" cosmetics platform company. It designs, formulates, sources packaging for, outsources the manufacture of, quality-checks and ships finished colour-cosmetic and skincare products for third-party brands. Its customers are concentrated in North America and Europe. Historically CTK was an asset-light turnkey ODM intermediary. Sell-side research describes its client list as including global majors such as L'Oréal, Unilever and Estée Lauder, alongside indie brands. Since 2022 the company has repositioned around CTKCLIP, an online B2B "beauty creation" platform with low minimum order quantities aimed at indie brands. In 2025 it bought a US OTC/cosmetics manufacturing plant in Corona, California, which ended its purely factory-free model, and it added a biodegradable-plastics materials business in Canada. The result is a small-cap, export-oriented company (about 85% US and Europe revenue in 2024) in the middle of a capital-intensive transition. Revenue is recovering (+28.9% YoY in Q2 2026), but consolidated profitability is still negative on a trailing basis.


What the company does

In its own descriptions (2018 IR deck, recruitment materials, interviews), CTK presents itself as a full-service beauty provider. It covers trend research and content planning, product design, formula development, packaging engineering, marketing support, contract production, inspection and logistics, and delivers the whole package to brand owners on a turnkey basis. A long-standing differentiator in company materials is that CTK historically owned no cosmetics factory. It used selected external manufacturing capacity while keeping formulation know-how, packaging design and project management in-house. Sell-side coverage (Yuanta, February 2024) describes the model the same way: the company outsources production of finished cosmetics, exports most of it to global brands, and builds its value on planning, branding, marketing and R&D rather than on owned plants.

The company's 2024 IR book lists its principal business lines as cosmetics and cosmetic containers (packaging). DART-based summaries describe CTK as making and selling cosmetics and cosmetic containers mainly for the US, UK and EU markets, and as running CTKCLIP, a platform that provides beauty-related services (Investing.com, from company filings).

Business model and revenue model

Revenue streamNatureDisclosure status
Turnkey finished cosmetics (ODM/OEM via outsourced production)Product sales. CTK invoices finished goods, mostly in USDMain revenue driver. Sits within the CTKCLIP Division segment (about 94% of Q2 2026 revenue, DART via Butler.works)
Cosmetic packaging/containersProduct sales of primary packaging designed by CTKIncluded in the core segment. Separate split n/d
Re-orders from existing customersRecurring product revenue. Product life cycles at global clients typically run 3–5+ yearsRe-order share above 70% (Hana, Dec 2024). Expected to rise from 70% to 74% in 2024 (Yuanta, Feb 2024)
CTKCLIP platform (low-MOQ development for indie brands)Product sales originated through the platform. No subscription model disclosedPlatform revenue share n/d
US OTC/cosmetics contract manufacturing (CTK OTC Laboratories / "COL")Contract manufacturing service and product sales. Consolidated from 2025Company cited COL consolidation as a driver of Q2 2026 growth (Asia Economy, Aug 2026)
US fulfillment / 3PL (CTK USA Fulfillment Center)Logistics servicesCompany cited higher North American fulfillment volumes in Q2 2026 (Asia Economy, Aug 2026). Revenue n/d
Biodegradable resins and finished eco-products (CTK Bio / CTK Bio Canada)Materials and product salesAbout 2% of Q2 2026 revenue (Butler.works, DART)
Licensing / subscriptionNone disclosed—

Value-chain position

CTK sits upstream of brand owners. It acts as an integrator between brand marketing teams and the physical supply base: formula labs, filling plants, packaging moulders and decorators. In the North American value chain, CTK now runs a vertically linked chain from development (CTKCLIP) to manufacturing (CTK OTC Laboratories) to fulfillment (CTK USA Fulfillment Center). Its US manufacturing subsidiary describes this chain in its own directory listing (GCI Magazine).

Customer types and end-markets

Global multinational beauty groups: Hana Securities (Dec 2024) names L'Oréal, Unilever and Estée Lauder as major customers.

Retailer private label: Yuanta (June 2024) reports 11 new SKUs ordered for a large US retailer's "pure beauty" private-label line.

Indie and celebrity brands: Examples include Inn Beauty Project and SerumKind (Beauty Independent directory). KTB (2019) noted US celebrity brand launches.

Korean brands seeking US entry: The 2024–2025 OTC strategy targets Korean brand owners and Korean ODM/OEM peers that need FDA-compliant OTC production in the US (company IR, Dec 2024; eToday, Mar 2025).

Non-beauty (CTK Bio): Foodservice, packaging, public authorities and hemp-product distributors for compostable resins and finished goods. Named counterparties include the Charlotte Regional Visitors Authority, Everyday Hemp Company, NLC Energy, Star Group, a Sysco vendor registration and Blue Bottle Korea.

End-markets served are colour cosmetics (sell-side notes stress CTK's strength in make-up versus Korean ODM peers), skincare, suncare/OTC drug-cosmetics (sunscreen, acne care, skin protectants, sanitisers), and compostable packaging and consumer goods.

Independent characterisation

CTK is best understood as a project-based, North America-centric cosmetics supply-chain integrator. The original model was asset-light, cash-generative and dividend-paying: FY2017 operating margin was 21.6% (ETF Shopping, DART). It then went through a prolonged margin collapse (FY2020–FY2022) and has since tried three reinventions at once: an online platform for indie brands, a US owned-plant OTC strategy, and a biodegradable-materials venture. Revenue has stabilised at KRW 84–89bn a year in FY2023–FY2025. This is well below the KRW 110–124bn reached in FY2017–FY2021, and operating profitability has not yet returned on an annual basis. The 2025 acquisition moved the company from net-cash, low-leverage to a balance sheet with liabilities of KRW 110.5bn (FY2025), compared with KRW 34.7bn a year earlier.

Strategy

Stated strategic themes (company and IR, paraphrased)

  1. The CTKCLIP platform as the core growth engine. Create new brands on the platform while keeping re-orders from global clients (CEO, Asia Economy, Aug 2024). Plans have also been stated to add 3PL logistics, OBM design and retail solutions to the platform (Premium Beauty News).

  2. A North American one-stop chain for Korean beauty. Combine CTKCLIP development, COL manufacturing and US fulfillment into a single route to the US market for Korean brands and ODM peers. A VP interview (TheVC news feed) framed this as going beyond the "factory-free ODM" model.

  3. US OTC leadership. Use the FDA-audited Corona plant to address MoCRA tightening and the high FDA import-refusal rate for Korean sunscreens. Target: USD 30m+ in incremental annual revenue by 2027 (eToday, Mar 2025).

  4. Eco-materials. Scale CTK Bio's compostable resins as single-use plastic bans (Canada SUPPR, Korea's de-plastic roadmap) create demand.

  5. Shareholder returns. Keep paying dividends (ten consecutive years). Use a differential dividend that favours minority holders and qualify as a "high-dividend company" for separate dividend taxation (Finance Scope, Apr 2026).

Initiatives in the last 24 months (Oct 2024 – Oct 2026)

InitiativeDateDetailStatus
US OTC plant acquisition (COL)Announced Dec 2024; closed Mar 2025About KRW 27.9bn; funded by a capital injection into CTK USA Holdings plus a CBFull operation from Q4 2025. Utilisation improvement is a H2 2026 priority
IR Day13 Dec 2024Strategy presentation to 27 institutionsCompleted
North America OTC Strategic TFMar 2025Sales push for suncare, basic OTC and colour OTC; R&D and capacity-sharing with Korean ODM/OEMsOngoing
CTK Bio – Everyday Hemp partnershipJun 2025Hemp-based compostable straws (1m/month) and co-developmentOngoing
CTK Bio SUPPR compliance platformAug 2025Materials, finished goods and manufacturing integration for CanadaOngoing
CTK Bio long-term supply2,025USD 3m per yearOngoing
Cost efficiency / turnaround2,026Management credited cost efficiency for the Q2 2026 swing to operating profitIn progress
Differential dividendFeb–Apr 2026KRW 110 general / KRW 60 largest shareholderPaid 16 Apr 2026
CTK Bio public-sector demonstrationSep 2026Free resin for 160,000 municipal waste bags (Yongsan-gu)Completed

Medium-term targets and guidance

TargetValueSourceOutcome
2024 revenue growth+15–20% YoYYuanta (Jun 2024)Missed (−6.0%)
2024 operating margin7–8%Yuanta (Jun 2024)Missed (0.2%)
CTK Bio Canada 2024 revenueUSD 3m at break-evenYuanta (Jun 2024)—
2025 revenue / OPKRW 117.3bn / KRW 12.4bnHana (Dec 2024, citing company)Missed (KRW 89.2bn / −KRW 5.7bn)
OTC incremental revenueUSD 30m+ per year by 2027eToday (Mar 2025)Pending
H2 2026Continued improvement from ODM growth, fulfillment stabilisation and better COL utilisation (qualitative)Asia Economy (Aug 2026)Pending

ESG and sustainability commitments: no quantified corporate emissions or sustainability targets were found. Sustainability is expressed mainly through CTK Bio's product strategy.

Products & Services

CTK does not publish a public price list or SKU catalogue. The table below lists every offering identified in public materials. Pricing is not publicly disclosed for any line.

Core cosmetics platform (CTKCLIP Division)

OfferingDescription / capabilitiesTarget customerLaunch / latestFlagship examples
Turnkey full-service developmentTrend research, product concept, formula, packaging, decoration, marketing support, outsourced filling, QC and logistics in one packageGlobal brands, retailers, indie brandsSince 2001Re-order programmes with global brands (L'Oréal, Unilever, Estée Lauder per Hana, Dec 2024)
Colour cosmeticsMake-up formulas and packages. Sell-side notes highlight colour as CTK's competitive edge over Korean ODM peersGlobal and indie colour brandsOngoing—
SkincareTurnkey skincare formulas and packagingBrands, retailersOngoingSerumKind (turnkey formulation and packaging, 2019–present per Beauty Independent)
Primary and secondary packagingInnovative containers, decoration, customisation; company claims many award-winning packagesBrandsSince 1979 roots"Mix Creative" packaging project (2019, Beauty Independent)
Retailer private labelDevelopment of private-label lines for US retailMass and prestige retailers2,02411 SKUs for a large US retailer's pure-beauty PB line (Yuanta, Jun 2024)
Vegan / cruelty-free productionCapability listed in company directory profileClean-beauty brands——
CTKCLIP.comOnline B2B platform that matches curated formulas, packaging and raw materials to client briefs within a few clicks. Supported by in-house chemists ("CTK INOLAB") and packaging engineers. MOQ from 1,000 unitsIndie brands, creators, start-ups, Korean brandsLaunched Jun 202236,000+ partners (Dec 2024 IR Day); 46,000 clients within about 2 years of launch (ValueFinder, Jul 2025)
OTC cosmetics development serviceDevelopment of FDA-compliant OTC products (suncare, acne care)North American brandsLaunched mid-2024—
Own / incubated brandsSerumKind was described as an own brand entering the largest US home-shopping channel (2021)Consumers (via partners)2,021SerumKind

US manufacturing — CTK OTC Laboratories (COL)

OfferingDescriptionCapacity / certifications
OTC manufacturingSunscreen, acne care, skin protectants and sanitisers under FDA OTC monograph rulesFDA-registered, FDA cGMP, ISO 22716. 40,000 sq ft plant plus 30,000 sq ft adjacent warehouse (GCI Magazine listing)
Personal care and colour cosmeticsCustom formulation, automated filling and packagingSame facility
Private label / contract manufacturingBath and body, colour cosmetics, fragrance, oral care, suncareSame facility
OTC solutions for Korean ODM/OEMsContract OTC production and regulatory pathway for Korean peers' US-bound productsStrategic TF launched Mar 2025 (eToday)

Logistics and e-commerce

OfferingDescriptionStatus
CTK USA Fulfillment CenterUS 3PL / e-commerce fulfillment linked to CTKCLIP and COL. A collaboration with ShipBob was reported in 2021Volumes rising in Q2 2026 (Asia Economy, Aug 2026)
PopinBorder (CTK eVision)Cross-border bridge that links overseas suppliers (e.g., iHerb) to Korean marketplacesLaunched early 2021. Current status n/d

Eco-friendly Materials (CTK Bio / CTK Bio Canada)

OfferingDescriptionCertifications / customers
Compostable resins (PBAT-PHA compounds, masterbatch)Proprietary compounding of compostable and recyclable resins without PLA or virgin plastic; inputs include upcycled hemp, lignin, sawdust and agaveTÜV Austria OK compost HOME, US FDA, Health Canada, SGS, RespirTek, KOTITI (Asia Economy, Apr 2024; FN News, Jun 2025)
"Earth Edition" filmCompostable stretch/pallet filmNLC Energy (2023)
Compostable paper coatingsPaper laminated with proprietary compostable coatingCanada SUPPR compliance offering (Aug 2025)
Finished foodservice goodsCups, cutlery, strawsCharlotte Regional Visitors Authority (2024); Everyday Hemp Company (1m straws/month, 2025)
Cosmetic secondary packaging and waste bagsBiodegradable cartons and waste bagsTaesung Industry MOU for biodegradable cosmetic containers (Cosmorning; date not confirmed); Yongsan-gu bag programme (Sep 2026)
Long-term supplyUSD 3m/year long-term supply contract signed in 2025 (counterparty n/d)Finance Scope (Apr 2026)

Financial Narrative

All figures are consolidated K-IFRS, KRW bn, fiscal years ending 31 December. Primary source: DART annual reports as compiled by ETF Shopping (etfshopping.com/stock/260930). Supplementary sources: Valueline (DART-based) and Butler.works. Blank cells mean not publicly retrieved.

Income statement

Notes. FY2021: Butler.works reports revenue of KRW 115.1bn and operating loss of KRW −14.3bn, against KRW 113.8bn / −11.9bn (ETF Shopping, Yuanta). The difference probably reflects a restatement or consolidation-scope change; both are noted. FY2025 EBITDA and pre-tax come from Valueline (DART-based). Valueline shows attributable EPS of KRW −363 against −373 (ETF Shopping). Diluted EPS n/d. FY2025 DPS: KRW 110 for general shareholders and KRW 60 for the largest shareholder.

Margins

Revenue CAGR. FY2021→FY2025: −5.9% a year. FY2022→FY2025: +8.7% a year. For long-run context, FY2017 revenue was KRW 113.0bn, so revenue in FY2025 is about 21% below its listing-year level (ETF Shopping, DART).

Long-run context (FY2017–FY2020)

Source: ETF Shopping (DART): ### Quarterly trajectory (most recent ten quarters)

Source: ETF Shopping (DART quarterly and half-year reports). Q1-25 revenue is derived from the reported +24.4% YoY growth in Q1-26. Q1-25 operating income is derived from the FY2025 total less Q2–Q4. Q3-25 net income is derived from Valueline TTM data. These three derived values are approximations.

Trailing twelve months to June 2026 (Valueline, DART-based): revenue KRW 100.5bn (the first TTM figure above KRW 100bn since FY2021), gross profit KRW 39.8bn, SG&A KRW 47.4bn, operating loss KRW 7.5bn, EBITDA −KRW 2.8bn, net loss KRW 15.0bn, interest expense KRW 4.3bn.

Balance sheet

Sources: Valueline balance sheet (FY2022–FY2025, consolidated). ETF Shopping (DART) for FY2021 liabilities and equity; FY2021 total assets are derived by adding the two. Interim 31 Mar 2026: total assets KRW 267.7bn, liabilities KRW 122.5bn, equity KRW 145.2bn, cash KRW 13.7bn (Valueline). They are in the DART notes.

Net debt. Not computable from the retrieved data. The FY2025 jump in liabilities (+KRW 75.8bn YoY), the rise in interest expense to KRW 2.4bn in FY2025 and KRW 4.3bn TTM, and derivative losses booked in finance costs all point to a meaningful borrowing and convertible-bond position. The company moved from a net-cash position to a likely net-debt position in 2025, but the exact amount is not publicly disclosed in the sources accessed.

Cash flow

Sources: ETF Shopping (DART): cash change, FY2025 FCF, dividends and buybacks. Earlier buybacks: KRW 0.2bn (FY2017), KRW 7.7bn (FY2018), KRW 2.3bn (FY2019), KRW 5.0bn (FY2020).

Ratios

ROE, ROA and asset turnover are computed on period-end equity and assets from the tables above. FY2025 ROE and ROA match ETF Shopping (−5.0%, −2.9%). ROIC, current ratio, debt/equity on financial debt, net debt/EBITDA and cash conversion cycle cannot be computed without the debt and working-capital detail, so they are not publicly disclosed in the sources accessed. Inventories were KRW 3.2–6.4bn in 2022–2025E (Kiwoom, Jul 2025), which is consistent with an asset-light model with low inventory.

Commentary: trends, inflections and drivers

Revenue. The FY2022 collapse (−39%) followed the loss of volume at key global customers. Earlier, the FY2018–FY2019 notes from KTB show heavy dependence on one customer ("I company", running at about USD 14–20m a quarter). Yuanta later wrote that 2023 sales were hit by indie-brand attrition but offset by global brands. Recovery since then has been uneven. Revenue grew 28% in FY2023, fell 6% in FY2024 as a major client deferred orders in Q1, and grew 7% in FY2025. Quarterly revenue is volatile: Q3-25 was KRW 31.1bn and Q4-25 was KRW 16.0bn. This reflects project-based ordering. The H1 2026 rebound (+24% and +29% YoY) is the strongest two-quarter run since 2021. Management credits Korean-beauty demand at the HQ ODM business, higher US fulfillment volume and the consolidation of COL.

Gross margin. Gross margin has improved structurally, from 22–33% in FY2017–FY2021 to 37.8–39.5% in FY2023–FY2025. The drivers are a higher re-order mix (Yuanta: re-orders carry higher margins) and container sales. Gross margin dipped slightly in TTM June 2026 (39.6%) as manufacturing revenue with a different cost structure was added.

Operating income. The problem sits below gross profit. SG&A rose from about KRW 33.9bn (TTM June 2025) to KRW 47.4bn (TTM June 2026), per Valueline. Within it, salaries rose from KRW 12.7bn to KRW 17.9bn and depreciation from KRW 3.7bn to KRW 8.7bn. These reflect the US plant and the larger group structure. In parent-only terms, payroll was 10.7% of parent revenue in FY2025 against 6.5% in FY2021 (ETF Shopping). The eco-materials business is also loss-making (Kiwoom).

Below the line. Finance costs of KRW 13.96bn in FY2025 (Valueline) include derivative losses (KRW 1.26bn in FY2025; KRW 6.38bn TTM June 2026), interest and FX. Together with fund valuation swings, they push net income consistently below operating income. TTM June 2026 net loss (−KRW 15.0bn) is twice the operating loss.

Guidance credibility. Management targets have repeatedly missed:

  • 2024 target of 15–20% revenue growth and 7–8% operating margin (Yuanta, Jun 2024), against an actual −6% and 0.2%.

  • 2025 company target of revenue KRW 117.3bn and operating profit KRW 12.4bn (Hana, Dec 2024), against an actual KRW 89.2bn and −KRW 5.7bn.

  • Kiwoom's 2025E of revenue KRW 98.3bn and operating profit KRW 2.0bn (Jul 2025) also overshot.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment (DART Label) Overview

Segment (DART label)What it containsShare of revenue (Q2 2026)Segment operating income / margin

CTKCLIP Division (CTKCLIP본부)

Turnkey cosmetics and packaging for global and indie brands; CTKCLIP platform; very likely also US OTC manufacturing and fulfillment (classification not confirmed)

~94%

—

Eco-friendly Materials (친환경소재)

CTK Bio / CTK Bio Canada compostable and recyclable resins and finished goods

~2%

n/d. Described as loss-making (Kiwoom, Jul 2025)

Other (기타)

Unclassified / other activities

~4%

—

Segment revenue (KRW Bn)

Segment revenue (KRW Bn)FY2023FY2024FY2025

Total consolidated revenue

88.983.689.2

Group Entities

EntityCountryRoleOwnershipLatest data

CTK Co., Ltd

Korea

Listed parent; HQ; sales, R&D, packaging design

—

Parent revenue FY2025 KRW 67.9bn (ETF Shopping, DART)

CTK USA Holdings Corporation

USA

US holding company for OTC plant and fulfillment

100%

Total assets KRW 73.9bn; net loss KRW 1.53bn (DART FY2025 via ETF Shopping)

CTK OTC Laboratories, LLC ("COL")

Corona, California, USA

FDA-registered OTC and cosmetics manufacturing

Indirect (via CTK USA Holdings)

40,000 sq ft plant plus 30,000 sq ft warehouse (GCI Magazine listing)

CTK USA Fulfillment Center

USA

3PL / e-commerce fulfillment

Indirect

—

CTK eVision

USA

Cross-border e-commerce (PopinBorder)

——

CTK Bio Canada / CTK Bio

Surrey, BC, Canada (Korean entity also referenced)

Compostable resin compounding and finished products

Described in Korean press as a second-tier subsidiary of CTK

—

Smilegate Aphrodite PEF

Korea

Financial investment vehicle

60%

Total assets KRW 7.3bn

Regent Cross-border New Technology Investment Association

Korea

Investment vehicle

84.75%

Total assets KRW 1.1bn

Smilegate Aphrodite Sub-One Fund

Korea

Fund

19.05%

Total assets KRW 10.0bn

Minority investments

Korea / Singapore / US

Colosseum Corp. 6.27%; 2022 SBI Innovation Growth Fund 2.17%; Premier IBK KDB K-Bio Vaccine Fund 1.92%; Livicon 1.79%; Muse M 1.39%; Lukla Inc. (OROS) 1.24%; Endowus Technologies 0.39%

Various

ETF Shopping (DART FY2025)

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

113.869.488.983.689.2

Revenue growth YoY (%)

-8.3-39.128.2-6.06.7

Cost of sales (KRW Bn)

80.547.555.351.253.9

Gross profit (KRW Bn)

33.321.933.632.435.3

Operating income (KRW Bn)

-11.9-15.22.70.1-5.7

EBITDA (KRW Bn)

————1.5

Pre-tax income (KRW Bn)

————-7.1

Net income (KRW Bn)

-3.9-21.26.2-3.7-7.3

EPS basic (KRW)

——369-173-373

Dividend per share, general shareholders (KRW)

10050100100110

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

Metric (%)FY2021FY2022FY2023FY2024FY2025

Gross margin

29.231.537.838.839.5

Operating margin

-10.5-21.93.10.2-6.4

EBITDA margin

————1.6

Net margin

-3.4-30.57.0-4.5-8.2

Income Statement and Margin Analysis (%) (FY2017–FY2020)

MetricFY2017FY2018FY2019FY2020

Revenue (KRW Bn)

113.0110.5116.3124.2

Gross margin (%)

31.322.426.933.1

Operating income (KRW Bn)

24.45.24.00.5

Operating margin (%)

21.64.73.40.4

Net income (KRW Bn)

15.37.87.2-2.0

EPS (KRW)

1,853796797—

Financial Analysis

Metric (KRW Bn)Q1-24Q2-24Q3-24Q4-24Q1-25Q2-25Q3-25Q4-25Q1-26Q2-26

Revenue

18.423.124.217.919.722.531.116.024.529.0

Operating income

-0.80.70.5-0.20.40.2-4.1-2.2-1.70.5

Net income

-0.70.40.7-4.1——-4.8-3.7-4.6-1.9

Balance Sheet

Metric (KRW Bn)FY2021FY2022FY2023FY2024FY2025

Total assets

208.3178.7189.7191.2256.8

Current assets

—81.687.477.565.6

Cash and cash equivalents

—35.816.931.59.5

Short-term financial assets

—16.219.06.511.1

Total liabilities

29.627.731.234.7110.5

Total equity

178.7151.0158.5156.5146.3

Cash Flow

Metric (KRW Bn)FY2021FY2022FY2023FY2024FY2025

Net change in cash

14.0-13.4-19.013.4-21.3

Free cash flow

————-33.5

Dividends declared for the year

1.80.51.51.51.7

Share buybacks

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2021FY2022FY2023FY2024FY2025

ROE (%)

-2.2-14.03.9-2.4-5.0

ROA (%)

-1.9-11.93.3-1.9-2.9

Liabilities / equity (%)

16.618.319.722.275.5

Asset turnover (x)

0.550.390.470.440.35

Interest coverage, EBIT / interest (x)

————-2.4

Dividend payout (%)

——21——

Region (% of Revenue) Overview

Region (% of revenue)FY2024Q1-25

North America

—76.5

Korea (domestic)

—10.4

Europe and Asia

—13.1

US plus Europe combined

8589.6

Valuation Snapshot

MetricValueSource

Last close (19 Oct 2026)

KRW 2,230

ETF Shopping

52-week range

KRW 2,130 – 5,110

ETF Shopping

1-month return

-3.7%

ETF Shopping

6-month return

-45.4%

ETF Shopping

1-year return

-55.3%

ETF Shopping

3-year return

n/d (price on 23 Feb 2024 was KRW 5,160, Yuanta)

—

Historical high-water mark

KRW 28,650 on 19 Jul 2018, market cap about KRW 302.6bn (Hankyung). The share count has since changed: about 10.6m shares implied in 2018 against 19.34m now, so prices are not directly comparable

Hankyung (Jul 2018)

Share Price and Market Valuation

MetricFeb-2024Jun-2024Jul-2025Mar-2026Apr-2026Oct-2026

Share price (KRW)

5,1606,9004,5753,9853,9502,230

Market cap (KRW Bn)

99.8133.588.5——43.1

Valuation Multiples

MultipleCTKPeer referenceSource

P/E (TTM)

Not meaningful (loss-making). Valueline shows −3.0x

Cosmax ~18x, Kolmar ~15x (forward, as cited in Hana's Cosmecca note, Jul 2025)

Valueline; Hana

P/B

0.29–0.30x

—

ETF Shopping; Valueline

EV/EBITDA

Not meaningful (TTM EBITDA negative)

——

EV/Sales

Not computable (net debt n/d). Market cap / TTM sales ≈ 0.43x

—

Computed

Dividend yield

4.89% (KRW 110 / KRW 2,230)

—

ETF Shopping

Dividend per share (KRW)

Dividend per share (KRW)FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025

General shareholders

32020030020010050100100110

Total dividends (KRW Bn)

3.21.42.10.91.80.51.51.51.7

Analyst Conclusions

Management guidance

Qualitative (Aug 2026): continued improvement in H2 2026, driven by HQ ODM growth, stabilisation of North American fulfillment and better COL utilisation.

Quantitative: the only standing target is USD 30m+ in incremental OTC revenue by 2027 (Mar 2025). No FY2026 revenue or OP guidance was found.

Consensus

None available (no covering analysts publishing estimates).

Bull case

  1. The revenue inflection is real. H1 2026 revenue was KRW 53.5bn, up about 26% YoY, and TTM revenue passed KRW 100bn for the first time since FY2021. Q2 2026 shows operating leverage returning (OP +KRW 0.47bn).

  2. Strategic scarcity of the US OTC asset. With FDA refusing 57% of Korean sunscreen imports (Hana) and US tariffs in place, an FDA-registered West Coast plant fed by a 46,000-client platform could fill quickly. Reaching even half the USD 30m target would add about 25% to revenue.

  3. Valuation leaves room for error. At about 0.3x book (equity KRW 145bn against a market cap of KRW 43bn) with a 4.9% yield, a return to FY2023-level profit (KRW 2.7bn OP; KRW 6.2bn NI) could justify a material re-rating.

Bear case

  1. Balance-sheet strain. FY2025 FCF was −KRW 33.5bn, cash fell to KRW 9.5bn and liabilities tripled to KRW 110.5bn. TTM interest expense of KRW 4.3bn alone exceeds FY2023's operating profit.

  2. Credibility gap. Three successive targets (2024 growth and margin, 2025 KRW 117bn / KRW 12.4bn OP, Kiwoom's 2025E) missed by wide margins. Q2 2026's profit was only KRW 0.47bn and the quarter still lost KRW 1.9bn at the net level.

  3. Competitive crowding. Cosmax, Kolmar and Cosmecca/Englewood are expanding US OTC with balance sheets 20–30x larger. CTK's eco-materials and investment-fund activities dilute management focus and capital.

Key catalysts and monitorables (next 12 months)

Catalyst / monitorableTimingWhat to watch
Q3 2026 resultsMid-Nov 2026Whether Q2's operating profit holds; COL utilisation; net loss trend
Contents of the Sep and Oct 2026 large-shareholding filingsImmediateAny change in the founder's stake, pledges or CB conversions
FY2026 dividend decisionFeb 2027Ability to sustain KRW 110 DPS on negative FCF
FY2026 annual reportBy end Mar 2027Timely filing; debt and CB disclosure; COL goodwill and impairment
OTC customer winsOngoingNamed Korean ODM/OEM partners; sunscreen SKUs
CTK Bio contractsOngoingConversion of pilots (Yongsan-gu, Everyday Hemp) into recurring revenue
FX (USD/KRW)OngoingRevenue translation
US tariff and FDA policyOngoingOTC monograph changes; sunscreen ingredient approvals

Analyst verdict

CTK Co., Ltd is a special-situation turnaround in a structurally attractive niche, carried out by a sub-scale company with a weak execution record. The core franchise is real. The company has two decades of turnkey development for global beauty majors, a gross margin that has risen about ten points since FY2021 to 39.5%, and a CTKCLIP funnel that has gathered tens of thousands of indie-brand prospects. The 2025 purchase of an FDA-registered OTC plant in California is strategically coherent. It puts CTK at the junction of three trends: K-beauty's push into the US, FDA scrutiny of imported sunscreens, and tariff-driven reshoring.

The financial evidence so far is unconvincing, however. Revenue in FY2025 (KRW 89.2bn) remained about 28% below FY2020. Operating losses returned, and below the line the company is absorbing heavier interest, derivative and fund-valuation charges. In one year the balance sheet moved from conservatively financed (liabilities at 22% of equity) to meaningfully levered (76%). Cash at the end of FY2025 was under KRW 10bn, and free cash flow was −KRW 33.5bn. Management has missed its own targets by wide margins, and the late FY2024 annual report adds a governance question.

Q2 2026 is the first datapoint consistent with the bull thesis: revenue grew 29% and the operating line turned slightly positive. That alone does not prove the model. What matters over the next two to three quarters is whether COL utilisation and the OTC partner pipeline produce sustained positive EBITDA without new dilutive financing. At about 0.3x book and a near-5% yield, the market is pricing substantial distress. Stance: speculative, with high dispersion of outcomes. Investors should require evidence of two or more consecutive profitable quarters, disclosure of the debt and CB terms, and named OTC customer wins before treating the discount to book as value rather than a value trap.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenure / backgroundAge / birth yearSource

Chung In-yong (정인용; "Ian Chung")

Founder, CEO and Representative Director; largest shareholder

Founded CTK in 2001 from a family packaging/metals business (1979 roots). Led the 2017 IPO. Based mostly in the US during 2019 growth projects (KTB)

Born 1972

Yahoo Finance; Money Today; KTB

Hong Chang-yoon (홍창윤)

Inside Director, overall management planning

—

Born 1960

Yahoo Finance

Choi Chi-ho (최치호; "Cheeho Choi")

President, Cosmetics CIC / Beauty Division

——

Asia Economy (Dec 2024); Yahoo Finance

Lee Jong-ho (이종호)

Vice President, Investment & Finance (formerly head of finance and the officer responsible for the FY2021 annual report); listed as a related party holding 0.01%

——

Asia Economy (Dec 2024); FY2021 annual report; ETF Shopping

Kim Yoon-tae (김윤태)

Vice President, Group Strategy

——

Asia Economy (Dec 2024)

Park Jin-geun ("JK Park")

CEO, CTK Bio / CTK Bio Canada

——

Asia Economy; Newsis

Daniel Shum

COO, CTK Bio

Founding team reportedly former professional athletes and fitness entrepreneurs

—

Bioplastics Magazine; Waste & Recycling Magazine

Workforce Metrics

ItemFY2025Source

Average pay per director/auditor (6 persons)

KRW 98m

ETF Shopping (DART FY2025)

Multiple of average employee pay

1.7x (employee average KRW 56.24m)

ETF Shopping

Individual pay disclosure

None. Korean rules require individual disclosure only above KRW 500m, and no individual is disclosed

ETF Shopping

Major Shareholders

HolderStake (%)Date / source

Chung In-yong (CEO)

39.69

FY2025 (ETF Shopping, DART)

Park Bo-ran (related party)

0.96

FY2025

Chung Gu-ju, Chung Ye-ju, Chung Yu-ju, Chung Gu-jun, Chung Eun-suk, Chung Hee-suk (related parties)

0.96 each

FY2025

Chung Yu-suk (related party)

0.73

FY2025

Lee Jong-ho (related party)

0.01

FY2025

Largest shareholder plus related parties

47.12

FY2025 (49.41% at FY2021; 47.72% FY2022; 47.71% FY2023; 47.12% FY2024)

Employee Stock Ownership Association

2.05

Investing.com shareholder table (date n/d)

Treasury shares

2.57

Butler.works

Minority shareholders (10,678 holders)

39.27

FY2025 (ETF Shopping)

Foreign ownership

1.6

Kiwoom (Jul 2025)

Institutional top 10 holders

—

Butler.works

“—” = not publicly disclosed.

Competitive Landscape

Key Competitors

CompetitorSegment overlapScale / latest dataPositioning vs CTK

Cosmax (KOSPI)

Cosmetics ODM (global #1 by its own claim); US plant

FY2025 revenue KRW 2,398.8bn (+10.7%); OP KRW 195.8bn; US subsidiary revenue KRW 132.6bn (Dealsite, Feb 2026)

About 27x CTK's revenue. Owns plants; strong in Asia

Kolmar Korea (KOSPI)

Cosmetics and pharma ODM; Kolmar USA plants

FY2025 revenue KRW 2,722.4bn; OP KRW 239.6bn, including HK inno.N (Kuki News, Feb 2026). FY2024 US subsidiary revenue KRW 57.9bn (+55%)

Diversified. Expanding US suncare and OTC directly

Cosmecca Korea (KOSDAQ) / Englewood Lab (US)

ODM; US OTC and suncare via Englewood Lab

FY2024 OP KRW 60.4bn. 2025 forecast revenue ~KRW 550bn, OP ~KRW 68bn (analyst estimates). US OTC SKU growth in 2H25

Closest analogue for the "Korean ODM with US OTC plant" thesis

Englewood Lab (KOSDAQ)

US-based OTC/skincare ODM

FY2024 OP KRW 18.8bn (CosinKorea)

Direct US OTC competitor

C&C International (KOSDAQ)

Colour-cosmetics ODM (lip, eye)

FY2024 OP KRW 29.0bn (CosinKorea); 2020 revenue KRW 89.6bn

Direct competitor in colour, CTK's strength

Intercos Korea / Intercos (Italy)

Global colour-cosmetics ODM

Intercos Korea FY2024 OP KRW 23.0bn (CosinKorea). Group figures n/d

Global colour leader

Yonwoo (KOSDAQ)

Cosmetic packaging

—

Packaging overlap (TheVC lists as a similar company)

The Codi (KOSDAQ)

Cosmetics ODM/OEM

—

Small-cap peer (TheVC lists as similar)

Cosnine

Cosmetics ODM

—

Peer (TheVC)

Sunjin Beauty Science

Raw materials; OTC ambitions

—

OTC-adjacent (Metro Seoul, Dec 2024)

PLA and compostable-resin suppliers (various)

CTK Bio materials

—

CTK Bio positions against PLA

Peer Comparison FY2025

MetricCTKCosmaxKolmar Korea

Revenue FY2025 (KRW Bn)

89.22,398.82,722.4

Revenue growth FY2025 (%)

6.710.7—

Operating margin FY2025 (%)

-6.48.28.8

Gross margin FY2025 (%)

39.5——

R&D intensity (% of revenue)

0.7——

Recent Developments

The table lists every verifiable item found. Contract-win disclosures, litigation and workforce actions were not found in public sources.*

Company Snapshot

$62.8M

Revenue

129

Employees

2001

Founded

Seoul, South Korea

Headquarters

SWOT Analysis

Strengths

  • Structural gross-margin uplift. 39.5% in FY2025 versus 29.2% in FY2021 (ETF Shopping, DART).
  • Blue-chip client base with long product lives. L'Oréal, Unilever and Estée Lauder per Hana (Dec 2024), with a re-order share above 70%.
  • Owned FDA-registered US plant. 40,000 sq ft with ISO 22716 and cGMP, plus a 30,000 sq ft warehouse (GCI Magazine).
  • Platform reach. 36,000+ CTKCLIP partners (Dec 2024), rising to 46,000 clients (Jul 2025).
  • Controlling shareholder alignment. 47.12% held by the founder and related parties (FY2025) means stable control.
  • Consistent dividend record. Ten consecutive years, with KRW 110 DPS for FY2025 even in a loss year (Finance Scope, Apr 2026).

Weaknesses

  • Persistent operating losses. FY2025 OP −KRW 5.7bn; TTM June 2026 −KRW 7.5bn (Valueline).
  • Revenue below the listing-era peak. KRW 89.2bn in FY2025 against KRW 124.2bn in FY2020.
  • Balance-sheet deterioration. Liabilities rose to KRW 110.5bn from KRW 34.7bn; cash fell to KRW 9.5bn (FY2025).
  • Negative FCF of KRW 33.5bn in FY2025 (ETF Shopping).
  • Repeated guidance misses. 2025 target of KRW 117.3bn / KRW 12.4bn OP versus KRW 89.2bn / −5.7bn.
  • Minimal expensed R&D. About 0.7% of revenue in FY2025 (Valueline).
  • Reporting timeliness. FY2024 annual report filed 30 May 2025.

Opportunities

  • US OTC target of USD 30m+ in incremental revenue by 2027 (eToday, Mar 2025). At about KRW 1,400/USD this equals roughly 45% of FY2025 revenue.
  • Supplying Korean ODM/OEM peers with US OTC capacity amid FDA import refusals.
  • Tariff-driven reshoring of Korean beauty production to the US (ValueFinder).
  • CTK Bio's regulatory tailwinds. Canada SUPPR, the Korean de-plastic roadmap, and a USD 3m/year contract.
  • H1 2026 revenue momentum (+24% and +29% YoY), with operating profit in Q2 2026.
  • Deep discount to book. P/B about 0.29x means that a credible turnaround could re-rate the shares.

Threats

  • Larger peers expanding US OTC capacity: Cosmax USA (KRW 132.6bn of revenue), Kolmar USA (+55% in 2024), Cosmecca/Englewood.
  • Client concentration and order timing. Q1 2024 revenue fell 24% because a major client deferred orders (Yuanta, Jun 2024).
  • FX reversal. Revenue is USD-heavy, and the company has acknowledged a tailwind from a weak won.
  • Rising financing costs and derivative volatility. Interest expense of KRW 4.3bn TTM; derivative losses of KRW 6.4bn TTM (Valueline).
  • Policy risk for bio-plastics. Regulatory rollbacks or PLA price competition.
  • Equity dilution if convertible bonds convert or new capital is needed. The shares are at multi-year lows.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Apr 2025Yuanta note: US and Europe made up about 85% of FY2024 revenue; global-brand share rose in 2024 despite indie attrition in 2023Confirms export concentration
30 May 2025FY2024 annual report and Q4 2024 results filed on DART (FY2024 OP KRW 0.1bn; NI −KRW 3.7bn)Filing about two months after the usual deadline. Reason n/d. A governance and reporting watch-point
9 Jun 2025CTK Bio – Everyday Hemp Company partnership (1m straws/month)First scaled North American hemp-product channel
11 Jul 2025Kiwoom initiation-style brief (Not Rated). 2025E revenue KRW 98.3bn, OP KRW 2.0bn. COL full operation expected Q4 2025Sell-side framework for OTC and eco upside
23 Jul 2025ValueFinder note: CTKCLIP passed 46,000 clients; Sysco vendor registration; Blue Bottle Korea contractPositive sentiment; de-plastic policy theme
Jul 2025Shares rally on Korean government's "de-plastic roadmap" theme (Asia Economy feature)Thematic trading
5 Aug 2025CTK Bio launches an end-to-end SUPPR compliance platform in CanadaProduct extension
14 Aug 2025Q2 2025: revenue KRW 22.5bn (−2.8% YoY); OP KRW 0.2bn (−68% YoY)Weak first half
2025CTK Bio signs USD 3m/year long-term supply contractMaterials revenue visibility
Q4 2025US OTC plant (COL) begins full operationStart of consolidated US manufacturing
14 Nov 2025Q3 2025: revenue KRW 31.1bn (+28.6% YoY) but operating loss KRW 4.1bnGrowth with heavy start-up costs
2025 (published 2026)CTK Bio wins two 2025 BASA AwardsThird-party validation of materials technology
20 Feb 2026Board approves FY2025 cash dividend (total about KRW 1.7bn; differential KRW 110 / KRW 60)Tenth consecutive dividend despite losses
13 Mar 2026IR "key business status" presentationInvestor communication
20 Mar 2026FY2025 annual report: revenue KRW 89.2bn, OP −KRW 5.7bn, NI −KRW 7.3bn, FCF −KRW 33.5bn; liabilities KRW 110.5bnLeverage step-up confirmed
7 Apr 202625th AGM confirms dividend; company qualifies as a "high-dividend company" for separate taxationMinority-friendly capital return
16 Apr 2026Dividend paid—
15 May 2026Q1 2026: revenue KRW 24.5bn (+24.4% YoY); OP −KRW 1.7bn; NI −KRW 4.6bnTop-line recovery, still loss-making
27 May 2026IR "key business status" presentationInvestor communication
10 Aug 2026Q2 2026 preliminary: revenue KRW 29.0bn (+28.9%); OP KRW 0.47bn (back in profit)First quarterly operating profit since Q2 2025
14 Aug 2026H1 2026 report filed; Q2 net loss KRW 1.9bnBelow-the-line drag persists
Aug–Sep 2026Shares fall to about KRW 2,200–2,700; 52-week low KRW 2,130Equity value near 0.3x book
3 Sep 2026Large-shareholding report (general) filedOwnership change; contents n/d
14 Sep 2026CTK Bio donates resin for 160,000 compostable waste bagsPublic-sector pilot data
7 Oct 2026Large-shareholding report and officer/major-shareholder ownership report filedPossible insider or major-holder transaction; contents n/d
19 Oct 2026Close KRW 2,230; market cap KRW 43.1bn; 1-year return −55.3%Valuation trough

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

2 charts
Revenue by Segment: Total consolidated revenue rose from KRW 88,900 Mn in FY2023 to KRW 89,200 Mn in FY2025.
CTK Co., Ltd — Revenue by Segment
Series (KRW Mn)FY2023FY2024FY2025
Total consolidated revenue88,90083,60089,200

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. DART filings as compiled by ETF Shopping: etfshopping.com/stock/260930; /company; /earnings (accessed Oct 2026)
  2. Valueline (DART-based): valueline.co.kr/finance/income/260930; /finance/balancesheet/260930
  3. Butler.works company page (DART summary, Q2 2026 segment mix, filing list)
  4. KIND/KRX: CTK FY2021 annual report (22 Mar 2022)
  5. Yuanta Securities: CTK notes (26 Feb 2024; 7 Jun 2024 · Apr 2025)
  6. Kiwoom Securities: CTK company brief (11 Jul 2025)
  7. Hana Securities via Asia Economy (13 Dec 2024): CTK IR Day via Asia Economy (16 Dec 2024)
  8. ValueFinder via Asia Economy (23 Jul 2025): Kiwoom via Asia Economy (11 Jul 2025)
  9. Asia Economy: Q2 2024 results (15 Aug 2024) · Q2 2026 preliminary results (10 Aug 2026) · CTK Investment sale (14 Dec 2022) · NLC Energy (8 Feb 2023) · CRVA (4 Apr 2024) · Yongsan-gu (14 Sep 2026)
  10. eToday: North America OTC TF (27 Mar 2025)
  11. Metro Seoul: OTC acquisition and capital injection (4 Dec 2024)
  12. Newsis / FN News: Everyday Hemp partnership (9 Jun 2025)
  13. Finance Scope: dividend and AGM (7 Apr 2026)
  14. Money Today: pre-IPO CEO interview (4 Dec 2017)
  15. KTB Investment & Securities: CTK Cosmetics note (19 Jun 2019)
  16. Insight: Q1 2021 results · Asia Economy (Apr 2021): PopinBorder
  17. CTK 2018 IR deck (Hong Kong): CTK IR book (Dec 2024)
  18. Premium Beauty News (CTKCLIP interview): Korea Product Post · Beauty Independent directory · GCI Magazine (CTK OTC Laboratories listing) · Salesforce customer story
  19. Bioplastics Magazine and Renewable Carbon (CTK Bio, Aug 2025): Waste & Recycling Magazine (BASA Awards, 2026) · Cosmorning (Taesung Industry MOU)
  20. Investing.com, Yahoo Finance, StockHub, TheVC (profiles and market data)
  21. Peers: Dealsite (Cosmax FY2025, Feb 2026) · Kuki News (Kolmar Korea FY2025, Feb 2026) · CosinKorea (Korean ODM FY2024 rankings) · Meritz, Hana and Hanwha notes on Cosmecca Korea · Bizwatch (Feb 2025)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.